利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.022 秒)

    Processes of preparing highly pure telmisartan form A, suitable for pharmaceutical compositions
    1.
    发明申请
    Processes of preparing highly pure telmisartan form A, suitable for pharmaceutical compositions 审中-公开
    制备高纯度替米沙坦形式A的方法，适用于药物组合物

    公开(公告)号：US20060276525A1

    公开(公告)日：2006-12-07

    申请号：US11434755

    申请日：2006-05-17

    申请人： Itai Adin ,  Carmen Iustain ,  Michael Brand ,  Ada Salman ,  Alexander Weisman

    发明人： Itai Adin ,  Carmen Iustain ,  Michael Brand ,  Ada Salman ,  Alexander Weisman

    IPC分类号： A61K31/4184 ,  C07D403/02

    CPC分类号： C07D235/20

    摘要： Processes are disclosed for preparing Telmisartan form A, which is free-flowing and which does not contain electrostatic charge and is thus industrially process-able. The free-flowing Telmisartan form A is prepared by crystallization from a polar organic solvent e.g., DMSO, DMF, DMA, NMP, or water and is suitable for use in pharmaceutical compositions. A process is also disclosed for preparing highly-pure Telmisartan form A by precipitation from aqueous solutions.

    摘要翻译： 公开了制备替米沙坦形式A的方法，其自由流动并且不含静电电荷，因此在工业上可加工。 自由流动的替米沙坦形式A通过从极性有机溶剂例如DMSO，DMF，DMA，NMP或水中结晶制备，并且适用于药物组合物。 还公开了通过从水溶液中沉淀制备高纯度的替米沙坦形式A的方法。

    Crystalline forms of halobetasol propionate
    2.
    发明授权
    Crystalline forms of halobetasol propionate 失效
    结晶形式的丙酸卤代倍他索

    公开(公告)号：US07208485B2

    公开(公告)日：2007-04-24

    申请号：US10341690

    申请日：2003-01-13

    申请人： Itai Adin ,  Yuri Futerman ,  Ori Lerman ,  Alexander Weisman ,  Chaim Ashkenazi ,  Joseph Kaspi

    发明人： Itai Adin ,  Yuri Futerman ,  Ori Lerman ,  Alexander Weisman ,  Chaim Ashkenazi ,  Joseph Kaspi

    IPC分类号： A61K31/56 ,  C07J7/00

    CPC分类号： A61K31/56 ,  C07J7/00

    摘要： The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6 herein.

    摘要翻译： 本发明提供一种选自由具有结晶形式I的特征为结晶形式I的权利要求的表示于表1中的功能X射线衍射峰位置和强度的结晶形式的盐酸羟钴因子， 如本文表2所示的X-射线衍射峰位置和强度，具有结晶形式III的盐酸羟考沙丹，其特征在于功能X射线衍射峰位置和强度，如表3所示，具有结晶形式IV的具有结晶形式IV的功能X- 如本文表4所示的X-射线衍射峰位置和强度，具有结晶形式V的具有由表X所示的功率X射线衍射峰位置和强度表征的结晶形式V的卤代双酚S和具有结晶形式VI的十六烷醇酯，其特征在于功率X 射线衍射峰位置和强度 如本文表6所示。